Results 201 to 210 of about 17,888 (258)

Magnesium as a Bioenergetic Checkpoint Linking Mitochondrial Function, Metabolic Disease, and Aging

open access: yesAging Cell, Volume 25, Issue 6, June 2026.
This review positions magnesium as a central bioenergetic checkpoint that orchestrates mitochondrial function and metabolic resilience. By defining the functional ATP pool and stabilizing mitochondrial performance, magnesium homeostasis serves as a mechanistic link between renal handling, metabolic disease, and the aging process.
Chien‐Wei Huang   +6 more
wiley   +1 more source

The Evolving Landscape of Clinical Aging Clocks: From Epigenetic to Multi‐Omics Integration

open access: yesAging Cell, Volume 25, Issue 6, June 2026.
Multi‐omics aging clocks capture biological heterogeneity beyond single‐omics models, improving risk stratification. Key challenges include unknown biological meaning, timescale mismatches, and validation gaps. Future clocks must distinguish pathological damage from adaptive remodeling—damage accumulation is the most actionable target for anti‐aging ...
Liying Liu   +13 more
wiley   +1 more source

Resolvin D1 attenuates senescence-associated secretory phenotype independently of TGF-β-driven cardiac fibroblasts differentiation to myofibroblast. [PDF]

open access: yesJ Inflamm (Lond)
Román M   +7 more
europepmc   +1 more source

Senescent Myoblasts Exhibit ROS‐Dependent Akt‐mTORC1 Dysregulation and Are Susceptible to Reductive Stress‐Induced Cell Death

open access: yesAging Cell, Volume 25, Issue 6, June 2026.
Senescent myoblasts exhibit dysregulated Akt/mTORC1 signalling. Antioxidants can alleviate this dysregulation, as well as other downstream senescent phenotypes. Moreover, prolonged antioxidant treatment can selectively induce cell death in senescent myoblasts, suggesting that these cells are more susceptible to reductive stress.
Vladimir Belhac   +13 more
wiley   +1 more source

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4529-4545, June 2026.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source

The In Vitro Wound‐Scratch Assay: Applications, Technical Advances, and Limitations in Wound Healing Research

open access: yesInternational Wound Journal, Volume 23, Issue 6, June 2026.
ABSTRACT The wound‐scratch assay is a widely used in vitro model for studying collective cell migration, a fundamental process contributing to wound closure and re‐epithelialisation. Owing to its simplicity, low cost, and adaptability, it has become a foundational tool for early‐stage wound‐healing research and therapeutic screening. The assay involves
Philisiwe F. Molefe   +3 more
wiley   +1 more source

Cellular senescence in migraine - a hypothesis-driven narrative review. [PDF]

open access: yesJ Headache Pain
Fila M   +5 more
europepmc   +1 more source

The aging paradox of Cushing's syndrome: Stress without clear senescence?

open access: yesJournal of Neuroendocrinology, Volume 38, Issue 6, June 2026.
Abstract Cushing's syndrome (CS), characterized by chronic endogenous hypercortisolism and disruption of the normal circadian cortisol rhythm, represents a unique human model for investigating the interplay between stress endocrinology and biological aging.
Israel Nunes Silveira   +1 more
wiley   +1 more source

Home - About - Disclaimer - Privacy